Researchers from the University of Florida have developed what they call a "nanozyme". Based around gold nanoparticles, these things have their surface coated with two biological agents. One is an enzyme that attacks and kills the mRNA which allows hep C to replicate, while the other is a short string of DNA which identities the disease and sends the enzyme off to kill it.
While current hep C treatments attack the same replication process, they only work on about 50 percent of patients treated. In lab-based tests, reported in the Proceedings of the National Academy of Sciences, the Univeristy of Florida researchers showed that their approach was 100 percent effective in both cell cultures and mice. They observed no side effects in the mouse models, either.
While it's great news, such a treatment is some way off becoming available to patients any time soon. All targeted drugs have to be extremely carefully tested, as there's always a risk that they could also end up targeting healthy parts of the body by accident. Given the current problems posed by hepatitis C, though, that testing can't happen soon enough. More here.